Senseonics Announces Equity Grants To Employees Under Inducement Plan
April 01 2021 - 7:55PM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM)
system for people with diabetes, announced that it had made equity
grants to new employees under its 2019 Inducement Plan (the “Plan”)
in accordance with NYSE American Company Guide Section 711(a).
On April 1, 2021, Senseonics Compensation Committee granted 5
new non-executive employees non-qualified stock options to purchase
an aggregate of 62,000 shares of the Company’s common stock as an
inducement for such employees to join the Company. The options have
an exercise price of $2.58 per share, which was the closing price
of the Company’s common stock on the NYSE American on April 1,
2021. In each case, 25% of the shares underlying the options will
vest on the first anniversary of the employee’s start date, with
the remainder vesting in monthly installments over the subsequent
three year period, in all cases contingent on such employee’s
continued service with the Company at the applicable vesting date.
Senseonics continues to work to bring its Eversense CGM System to
more people with diabetes in the U.S. and other markets around the
globe and drives to develop enhancements to the system.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration twice per day, and
when symptoms do not match CGM information or when taking
medications of the tetracycline class. The sensor insertion and
removal procedures are performed by a health care provider. The
Eversense CGM System is a prescription device; patients should talk
to their health care provider to learn more. For important safety
information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210401005966/en/
Lynn Lewis or Philip Taylor Investor Relations 415-937-5406
investors@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Sep 2023 to Sep 2024